Procedimiento para la Implementación Nacional de los Acuerdos
19 mar 2014 Con la base del. Acuerdo del CMDh la Comisión Europea emitirá una “Decisión de. Ejecución”. Medicamentos y. Productos Sanitarios. Page 3. b) ...
vancomycin: CMDh scientific conclusions and grounds for the
De acuerdo con las conclusiones científicas para vancomicina el CMDh considera que el balance beneficio-riesgo del medicamento o medicamentos que
quinapril: CMDh scientific conclusions and grounds for the variation
The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that
paracetamol (IV formulation): CMDh scientific conclusions and
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the
hydrochlorothiazide / spironolactone: CMDh scientific conclusions
De acuerdo con las conclusiones científicas para la hidroclorotiazida/espironolactona el CMDh considera que el balance beneficio-riesgo del medicamento o
Metamizole : CMDh Scientific conclusions and grounds for variation
The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that
vancomycin PSUSA-3097-202001 - CMDh position
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s).
Valproate: CMDh scientific conclusions and grounds for the variation
28 nov 2021 CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing valproic acid sodium valproate
Ethinylestradiol-Etonogestrel: CMDh scientific conclusions and
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s).
Fluconazole: CMDh scientific conclusions and grounds for the
The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s).
CMDh - Heads of Medicines Agencies
The CMDh started its activities in November 2005 replacing the informal Mutual Recognition Facilitation Group ( MRFG ) which was in operation over 10
Application for Marketing Authorisation ( MA
CMDh Guidance Document for Submission of Summary of the Pharmacovigilance System CMDh SOP on decision-making process for new active substance status or
[PDF] 31 CMDh update_A Ambrose
2005 – CMDh established under revised Pharmaceutical Legislation (Directive 2001/83/EC) ? 2012 – Responsibilities of CMDh extended
[PDF] Hydrocortisone: CMDh scientific conclusions and grounds for the
Le CMDh approuve les conclusions scientifiques formulées par le PRAC Motifs de la modification des termes de la/des autorisation(s) de mise sur le marché Sur
[PDF] Informations du CMDH - UPR info
Informations du C M D H Sur la situation des droits de l'Homme au Maroc Au titre de Année 2006 - 2007 L'an 2006 et les quatre premiers mois de 2007 se
[PDF] CMDh POSITION PAPER ON THE USE OF QR CODES TO
The provisions detailed in this CMDh paper to provide additional information about the medicinal product through a QR code are also applicable in case the
[PDF] CMDh Best Practice Guide on the processing of - GMP Navigator
1 nov 2020 · CMDh/004/2005 Rev 18 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures
[PDF] CMDh-Project for Harmonisation of RMPs (HaRP): Aims and results
PDF Portable Document Format PhV WSP Working Party Pharmacovigilance Work Sharing Procedures Working Party PI Product Information
[PDF] CMDh 399 2019 2019 04 Public consultation - AIFA
CMDh/399/2019 Public consultation 2 3 Recommendations on common regulatory approaches 4 for allergen products 5 Draft 6 Table of Contents
[PDF] CMDh Best Practice Guide on the processing of renewals in the
CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures Table of contents 1 Introduction
Annex I
Scientific conclusions and grounds for the variation to the terms of theMarketing Authorisation(s)
2Scientific conclusions
Taking into account the PRAC Assessment Report on the PSUR(s) for valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium, the scientific conclusions are as follows: In view of available data on eye malformations during in utero exposure from literature and spontaneous report s, PRAC considers a causal relationship between valproate and eye malformation isestablished. 23 cases of retinal fold/retinal rosette/retinal coloboma and coloboma in children exposed
to valproate in utero were noted. All cases were serious. In the majority of cases valproate was used
as monotherapy and daily valproate dose used by the mothers did not exceed the therapeutic dosage range. In 22/23 (95.7%) cases associated congenital malformations were reported, including 13 cases reporting fetal anticonvul sant syndrome. Narratives provided for the 23 cases indicate that 18 of the cases occurred in children with facial dysmorphism/dysmorphism. PRAC concludes that the product information (SmPC section 4.6 and PIL section 2) of products containing valproate should be amended accordingly.In addition, in view of the available dat
a, including 2 cases reporting on serum valproate levels and lack of seizure control when valproate was administered in patients on haemodialysis, PRAC considers the cumulative evidence sufficient to include a warning in SmPC section 4.2 that patients with end stage renal failure might experience lack of drug effect when they receive haemodialysis. Furthermore, in line with information provided in SmPC section 5.3 of other AED, PRAC agrees to include a wording on testicular findings of valproate use in adult and juvenile laboratory animals. The CMDh agrees with the scientific conclusions made by the PRAC. Grounds for the variation to the terms of the Marketing Authorisation(s)On the
basis of the scientific conclusions for valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnesium is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpromide, valproate bismuth, calcium valproate, valproate magnes ium are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position. 3Annex II
Amendments to the
product information of the nationally authorised medicinal product(s) 4 Amendments to be included in the relevant sections of theProduct Information (new text
underlined and in bold , deleted text strike through)Summary of Product Characteristics
• Section 4.6 In utero exposure to valproate may also result in hearing impairment or deafness due to ear and/or nose malformations (secondary effect) and/or to direc t toxicity on the hearing function. Cases describeboth unilateral and bilateral deafness or hearing impairment. Outcomes were not reported for all cases.
When outcomes were reported, the majority of the cases did not recover. In utero exposure to valproate may result in eye malformations (including colobomas, microphthalmos) that have been reported in conjunction with other congenital malformations. These eye malformations may affect vision.PIL section 2:
The risks of valproate when taken during pregnancy (irrespective of the disease for which valproate is
used): Talk to your doctor immediately if you are planning to have a baby or are pregnant. Valproate carries a risk if taken during pregnancy. The higher the dose, the higher the risks but all doses carry a risk. It can cause serious birth defects and can affect the way in which the child develops as it grows. The most frequently reported birth defects which have been reported include spina bifida (where the bones of the spine are not properly developed); facial and skull malformations; heart, kidney, urinary tract and sexual organ malformations; limb defects and multiple associated malformations affecting several organs and parts of the body. Birth defects may result in disabilities which may be severe. Hearing problems or deafness have been reported in children exposed to valproate during pregnancy. Eye malformations have been reported in children exposed to valproate during pregnancy in association with other congenital malformations. These eye malform ations may affect vision. If you take valproate during pregnancy you have a higher risk than other women of having a child with birth defects that require medical treatment. [...].Summary of Product Characteristics
• Section 4.2In patients with renal insufficiency
It may be necessary in patients with renal insufficiency to decrease the dosage, or to increase the dosage in patients on haemodialysis. < active substance> is dialysable (see section 4.9). Dosing should be modified according to clinical monitoring of the patient (see section 4.4).PIL section 3. How to X
5 Patients with kidney problems
Your doctor may decide to adjust your dose.
Summary of Product Characteristics
• Section 5.3 In repeat-dose toxicity studies, testicular degeneration/atrophy or spermatogenesis abnormalities and a decrease in testes weight were reported in adult rats and dogs after oral administration at doses of 1250 mg/kg/day and 150 mg/kg/day, respectively. In juvenile rats, a decrease in testes weight was only observed at doses exceeding the maximum tolerated dose (from 240 mg/kg/day by intraperitoneal or intravenous route) and with no associated histopathological changes. No effects on the male reproductive organs were noted at tolerated doses (up to 90 mg/kg/day). Based on these data, juvenile animals were not considered more susceptible to testicular findings than adults. Relevance of the testicular findings to paediatric population is unknown. In a fertility study in rats, valproate at doses up to 350 mg/kg/day did not alter male reproductive performance. However, male infertility has be en identified as an undesirable effect in humans (see sections 4.6 and 4.8). 6Annex III
Timetable for the implementation of this position
7Timetable for the implementation
of this positionAdoption of CMDh position:
October 2021 CMDh meeting
Transmission to National Competent Authorities
of the translations of the annexes to the position: 28 November 2021Implementation of the position by the Member
States (submission of the variation by the
Marketing Authorisation Holder): 27 January 2022
quotesdbs_dbs35.pdfusesText_40[PDF] edqm
[PDF] type de variation d'amm
[PDF] google gmail
[PDF] googlemail.com se connecter
[PDF] boite mail
[PDF] email hotmail
[PDF] créer un compte gmail
[PDF] gmail sign up
[PDF] compte google
[PDF] exercices pluriel des noms cm2 ? imprimer
[PDF] pluriel des noms en al ce2
[PDF] le pluriel des noms en ou
[PDF] le pluriel des noms en ail
[PDF] exercices pluriel des noms en al ail ou eu